Work

Lapatinib for Advanced or Metastatic Breast Cancer

Year: 2012

Type: review

Abstract: Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human epidermal growth factor receptor (HER)-2 that exerts its action by competitive binding to the intracellular ATP-binding site of the receptor. It is registered for the treatment of advanced or metastatic HER-2+ breast cancer in combination with capecitabine and for hormone receptor-positive breast cancer in combination with an aromatase inhibitor. Lapatinib administered orally once daily is moderately to well tolerated, with rash and gastrointestinal adverse events as the main toxicities. In studies on the efficacy of lapatinib, direct comparisons between lapatinib and trastuzumab are lacking. Results of ongoing randomized phase III studies with lapatinib or trastuzumab in combination with taxanes as first-line agents for metastatic breast cancer as well as in the neoadjuvant and adjuvant settings are awaited.

Source: The Oncologist

DOI: 10.1634/theoncologist.2011-0461

Authors: Frans L. Opdam, Henk-Jan Guchelaar, Jos H. Beijnen, Jan H.M. Schellens

Institutions: Leiden University, Leiden University Medical Center, The Netherlands Cancer Institute, Utrecht University, Slotervaartziekenhuis

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2169052701

FWCI: 0.741

Cites: 33

Cited by: 112

Related to: 10